Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Data show cyclosporine inhalation solution improves long-term survival in lung-transplant patients

11.04.2005


Inhaled therapy addresses most common cause of death among lung-transplant recipients



Data presented for the first time today at the 25th Annual Meeting and Scientific Session of the International Society for Heart and Lung Transplantation (ISHLT) show that cyclosporine inhalation solution (CyIS) significantly improves long-term survival in lung-transplant patients compared to placebo. The data, which include 10-month follow-up statistics on patients originally enrolled in the pivotal study of CyIS, show that, with a median total follow-up of 53.3 months, CyIS-treated patients demonstrated a continued survival advantage over placebo-treated patients. Treatment with CyIS was associated with a 69 percent decrease in risk of death compared to placebo.

"Analysis of the pivotal study presented at ISHLT last year indicated that CyIS prevents chronic rejection, the most common cause of death in lung-transplant recipients. These follow-up data indicate that the significant survival advantage of CyIS compared to placebo persists long-term," said Aldo Iacono, M.D., lead investigator of the study and Medical Director of the Lung Transplantation Program at University of Maryland Medical Center, Associate Professor of Medicine at the University of Maryland School of Medicine. "Despite the medical community’s best efforts, currently available immunosuppressive regimens have not been effective in reducing the incidence of chronic rejection or prolonging survival in lung-transplant patients. CyIS could be a breakthrough therapy to address this unmet need."


The randomized double-blinded, placebo-controlled pivotal study of CyIS was conducted at the University of Pittsburgh School of Medicine. The study began in 1998 and enrolled both single- and double-lung transplant patients who were already on standard, oral immunosuppressive therapies. Enrollment was completed in August 2001, and all subjects were followed until study completion in August 2003. Patients received either CyIS (n=26) or placebo (n=30), in addition to maintenance immunosuppression, and underwent an initial 10-day dose escalation phase to reach a maximum tolerated dose, up to 300 mg. Following initiation, patients received a maintenance dose of either the CyIS or placebo three times per week for two years. Upon completion of dosing, all subjects were followed for efficacy, including chronic rejection and survival, until the last enrolled subject completed the two-year period of dosing.

Analysis of data from the initial study period showed a 79 percent decrease in the risk of death for patients receiving CyIS compared to patients receiving placebo. Data from an additional 10 months of follow-up show that the survival duration for CyIS-treated patients remained significantly higher versus placebo-treated patients (log-rank p=.017). Estimated four-year survival was 84 percent in CyIS-treated subjects compared to 56 percent in placebo-treated subjects. The estimated hazard ratio (CyIS/placebo) of 0.31 corresponds with a 69 percent reduction in mortality.

CyIS therapy delivers cyclosporine directly to the lungs, achieving greater drug concentration at the site of rejection. A New Drug Application (NDA) for CyIS (tradename PULMINIQTM) was submitted to the U.S. Food and Drug Administration (FDA) by Chiron Corporation in October 2004 and is now under review. Cyclosporine in other formulations is a well-established immunosuppressive therapy for kidney, liver and heart transplant recipients. Currently, there are no FDA-approved therapies for the prevention of chronic rejection.

Compared to other organ transplants, long-term survival following lung transplantation has not improved appreciably in the last 10 to 15 years. According to 2004 ISHLT registry data of lung transplants performed between January 1998 and June 2002, one-year survival remains about 75 percent. At five years, survival remains approximately 45 percent, essentially unchanged since the late 1980s and early 1990s, and is significantly lower than survival rates following other solid organ transplants.

About Lung Transplant Rejection

Following transplantation there is an inherent risk of rejection, where the recipient’s immune system will recognize the donated lungs as foreign and attack the transplanted organ. Within the first three months, patients are at highest risk of acute rejection. However, as the patient moves out in time, the primary cause of death in up to 76 percent of cases is chronic rejection, which usually manifests after the first year. This is characterized by chronic inflammation and irreversible scarring of the lungs, a condition known as bronchiolitis obliterans.

Lauren Mason | EurekAlert!
Further information:
http://www.ishlt.org

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>